Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 25


Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.

Bennett JW, Yadava A, Tosh D, Sattabongkot J, Komisar J, Ware LA, McCarthy WF, Cowden JJ, Regules J, Spring MD, Paolino K, Hartzell JD, Cummings JF, Richie TL, Lumsden J, Kamau E, Murphy J, Lee C, Parekh F, Birkett A, Cohen J, Ballou WR, Polhemus ME, Vanloubbeeck YF, Vekemans J, Ockenhouse CF.

PLoS Negl Trop Dis. 2016 Feb 26;10(2):e0004423. doi: 10.1371/journal.pntd.0004423. eCollection 2016 Feb.


A global map of suitability for coastal Vibrio cholerae under current and future climate conditions.

Escobar LE, Ryan SJ, Stewart-Ibarra AM, Finkelstein JL, King CA, Qiao H, Polhemus ME.

Acta Trop. 2015 Sep;149:202-11. doi: 10.1016/j.actatropica.2015.05.028. Epub 2015 Jun 3.


Micronutrients and dengue.

Ahmed S, Finkelstein JL, Stewart AM, Kenneth J, Polhemus ME, Endy TP, Cardenas W, Mehta S.

Am J Trop Med Hyg. 2014 Nov;91(5):1049-56. doi: 10.4269/ajtmh.14-0142. Epub 2014 Sep 8. Review.


Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.

Lumsden JM, Nurmukhambetova S, Klein JH, Sattabongkot J, Bennett JW, Bertholet S, Fox CB, Reed SG, Ockenhouse CF, Howard RF, Polhemus ME, Yadava A.

Vaccine. 2012 May 9;30(22):3311-9. doi: 10.1016/j.vaccine.2012.03.004. Epub 2012 Mar 13.


Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine.

Moon JJ, Suh H, Polhemus ME, Ockenhouse CF, Yadava A, Irvine DJ.

PLoS One. 2012;7(2):e31472. doi: 10.1371/journal.pone.0031472. Epub 2012 Feb 6.


Antimalarial drug sensitivity profile of western Kenya Plasmodium falciparum field isolates determined by a SYBR Green I in vitro assay and molecular analysis.

Akala HM, Eyase FL, Cheruiyot AC, Omondi AA, Ogutu BR, Waters NC, Johnson JD, Polhemus ME, Schnabel DC, Walsh DS.

Am J Trop Med Hyg. 2011 Jul;85(1):34-41. doi: 10.4269/ajtmh.2011.10-0674.


Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion.

Lumsden JM, Pichyangkul S, Srichairatanakul U, Yongvanitchit K, Limsalakpetch A, Nurmukhambetova S, Klein J, Bertholet S, Vedvick TS, Reed SG, Sattabongkot J, Bennett JW, Polhemus ME, Ockenhouse CF, Howard RF, Yadava A.

Infect Immun. 2011 Sep;79(9):3492-500. doi: 10.1128/IAI.05257-11. Epub 2011 Jun 20.


Malaria prevalence defined by microscopy, antigen detection, DNA amplification and total nucleic acid amplification in a malaria-endemic region during the peak malaria transmission season.

Waitumbi JN, Gerlach J, Afonina I, Anyona SB, Koros JN, Siangla J, Ankoudinova I, Singhal M, Watts K, Polhemus ME, Vermeulen NM, Mahoney W, Steele M, Domingo GJ.

Trop Med Int Health. 2011 Jul;16(7):786-93. doi: 10.1111/j.1365-3156.2011.02773.x. Epub 2011 Mar 29.


Outpatient upper respiratory tract viral infections in children with malaria symptoms in Western Kenya.

Waitumbi JN, Kuypers J, Anyona SB, Koros JN, Polhemus ME, Gerlach J, Steele M, Englund JA, Neuzil KM, Domingo GJ.

Am J Trop Med Hyg. 2010 Nov;83(5):1010-3. doi: 10.4269/ajtmh.2010.10-0174.


Evaluation of recurrent parasitemia after artemether-lumefantrine treatment for uncomplicated malaria in children in western Kenya.

Woodring JV, Ogutu B, Schnabel D, Waitumbi JN, Olsen CH, Walsh DS, Heppner DG Jr, Polhemus ME.

Am J Trop Med Hyg. 2010 Sep;83(3):458-64. doi: 10.4269/ajtmh.2010.09-0403.


A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection.

Aronson NE, Wortmann GW, Byrne WR, Howard RS, Bernstein WB, Marovich MA, Polhemus ME, Yoon IK, Hummer KA, Gasser RA Jr, Oster CN, Benson PM.

PLoS Negl Trop Dis. 2010 Mar 9;4(3):e628. doi: 10.1371/journal.pntd.0000628.


Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.

Waitumbi JN, Anyona SB, Hunja CW, Kifude CM, Polhemus ME, Walsh DS, Ockenhouse CF, Heppner DG, Leach A, Lievens M, Ballou WR, Cohen JD, Sutherland CJ.

PLoS One. 2009 Nov 17;4(11):e7849. doi: 10.1371/journal.pone.0007849.


Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.

Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus ME, Walsh DS, Yoon IK, Prosperi C, Juompan LY, Lanar DE, Krzych U, Hall BT, Ware LA, Stewart VA, Williams J, Dowler M, Nielsen RK, Hillier CJ, Giersing BK, Dubovsky F, Malkin E, Tucker K, Dubois MC, Cohen JD, Ballou WR, Heppner DG Jr.

Vaccine. 2010 Jul 12;28(31):5135-44. doi: 10.1016/j.vaccine.2009.08.046. Epub 2009 Sep 6.


Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.

Polhemus ME, Remich SA, Ogutu BR, Waitumbi JN, Otieno L, Apollo S, Cummings JF, Kester KE, Ockenhouse CF, Stewart A, Ofori-Anyinam O, Ramboer I, Cahill CP, Lievens M, Dubois MC, Demoitie MA, Leach A, Cohen J, Ballou WR, Heppner DG Jr.

PLoS One. 2009 Jul 31;4(7):e6465. doi: 10.1371/journal.pone.0006465.


Bullous erythema multiforme after treatment with Malarone, a combination antimalarial composed of atovaquone and proguanil hydrochloride.

Remich SA, Otieno W, Polhemus ME, Ogutu B, Walsh DS.

Trop Doct. 2008 Jul;38(3):190-1. doi: 10.1258/td.2007.070192.


Malaria treatment with atovaquone-proguanil in malaria-immune adults: implications for malaria intervention trials and for pre-exposure prophylaxis of malaria.

Polhemus ME, Remich S, Ogutu B, Waitumbi J, Lievens M, Ballou WR, Heppner DG Jr.

Antimicrob Agents Chemother. 2008 Apr;52(4):1493-5. doi: 10.1128/AAC.01367-07. Epub 2008 Feb 11.


Persistence of vaccinia at the site of smallpox vaccination.

Cummings JF, Polhemus ME, Hawkes C, Klote M, Ludwig GV, Wortmann G.

Clin Infect Dis. 2008 Jan 1;46(1):101-2. doi: 10.1086/524078.


Hb G-Philadelphia or Stanleyville II? When the phenotype and genotype do not agree.

Waitumbi JN, Kifude CM, Withers MR, Polhemus ME, Heppner DG Jr, Ogutu BR.

Eur J Haematol. 2007 Aug;79(2):177-8. Epub 2007 Jul 2. No abstract available.


Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.

Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, Lanar DE, Dutta S, Barbosa A, Soisson L, Diggs CL, Robinson SA, Haynes JD, Stewart VA, Ware LA, Brando C, Krzych U, Bowden RA, Cohen JD, Dubois MC, Ofori-Anyinam O, De-Kock E, Ballou WR, Heppner DG Jr.

Vaccine. 2007 May 22;25(21):4203-12. Epub 2007 Mar 26.

Items per page

Supplemental Content

Loading ...
Support Center